Patients with Follicular Lymphoma, we need your help!
If you are a patient with relapsed/refractory follicular lymphoma and have been treated with Mosunetuzumab (Lunsumio) or Tafasitamab (Minjuvi), you can help by completing our survey.
Lymphoma Canada is preparing 2 submissions for Canada’s Drug Agency (CDA). This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
The therapies that will soon be reviewed by the CDA are:
- Mosunetuzumab (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
- Tafasitamab (Minjuvi) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a Follicular Lymphoma patient who has not received this therapy.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
It should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
